FDA approves Lipella's oral treatment access program
PITTSBURGH - Lipella Pharmaceuticals Inc. (NASDAQ:LIPO), a biotech firm specializing in novel therapies for medical conditions lacking adequate treatments, has received FDA approval for an Expanded ...
New Atlas8d
FDA approves new class of painkiller – the first in more than 20 years
The US Food and Drug Administration has approved the use of a novel painkiller as an effective treatment for short-term ...
Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus
The FDA’s approval for expanded use reinforces LP-310’s potential as a new therapeutic option for OLP and supports ongoing clinical development efforts.